John Libbey Eurotext

Bulletin du Cancer


Adjuvant chemotherapy with mitoxantrone, cyclophosphamide and 5-fluorouracile in breast cancer: patient’s experience Volume 84, issue 3, Mars 1997


See all figures

Inserm U. 379, Institut Paoli-Calmettes, 232, boulevard de Sainte-Marguerite, 13273 Marseille Cedex 9, France.

The chemotherapy side-effects are insufficiently documented while they strongly condition patients’quality of life. the aim of the study was to assess by means of a self-administered questionnaire the somatic symptoms experienced by breast cancer patients during their NCF (mitoxantrone + cyclophosphamide + 5-fluorouracil) chemotherapy and to demonstrate the interest of this self-report by comparing the frequency of side-effects assessed by the patients to that noted by the physicians in medical records. The study was carried out among 44 patients receiving their chemotherapy + radiotherapy at the Paoli-Calmettes Institute (Marseille) between July 1994 and May 1995. The questionnaire comprized of 17 symptoms evaluated in terms of frequency, duration/severity and distress. the most frequent symptoms are: hair loss and nausea (75%), hot flush (57%), lack of appetite and headache (46%) associated with distress in 67 to 100% of cases. Their frequency was underestimated by the physicians in medical records. This study showed a large discordance patient-physician in the assessment of chemotherapy side-effects. The type of tool presented in this study could complement the usual scales of toxicity that do not provide an estimation of true patients’ experience.